PRZOOM - /newswire/ -
Brookline, MA, United States, 2010/04/05 - Trial XL™, a web based solution for accelerating clinical trial operations of Pharmaceutical, Medical Devices and Biotech industry, launched as generally available.
Cognika Corporation announced the release of Trial XL™ version 2.1, a web-based decision support tool that helps users design clinical trials and improve efficiency of clinical operations. Built on Cognika’s ESP (Extraction, Simulation and Prediction) technology, Trial XL™ reveals novel insights extracted from an exhaustive analysis of all relevant historical trials. Trial XL™ Standard Edition integrates information from numerous public data sources and delivers retrospective analyses most relevant to the clinical trial. Trial XL™ Enterprise Edition integrates in-house historical clinical trial data and other proprietary data sources to provide additional meta-analysis resulting in improved likelihood of success of the clinical program.
Starting with initial protocol assumptions like therapeutic area or medical intervention, Trial XL™ uses its ESP technology platform to:
• Find relevant conditions, interventions. primary and secondary outcomes as well as inclusion and exclusion criteria associated with similar trials;
• Define and find intent to treat population based on historical information;
• Create ready to use relevant trials table and other analytics to justify operational decisions related to choice of Sites and Principal Investigators;
• Enable users to easily select or add other relevant attributes;
• Generate quantitative insights about patient enrollment rates, compliance and accrual.
Trial XL™ includes enhanced features like:
• Contextual Virtual Profiles created on-the-fly for every answer provided, including Sites and Relevant People;
• Hyperlinks to source articles of listing for complete justification of recommendations derived using the tool and;
• Easy import and export of information for offline analysis and report creation.
Using Trial XL™ to learn from past experiences will improve the likelihood of success, operational efficiency by identifying the parameters influencing its outcome.
The immediate benefit of using Trial XL™ is to reduce the time to create a clinical trial protocol by starting with a comprehensive analysis of available public data. In the long run it will reduce the cost of clinical trials by selecting the most efficient sites and the best experts for each trial. Pharmaceutical and Biotech companies also stand to benefit significantly by being able to reduce their overall clinical development cycle and bringing drugs to market earlier.
“After proving the strength of our ESP platform in analytics of proprietary data for Pharmaceutical companies for over four years, we are very excited to launch our first commercial solution as a ready to go web based product that provides valuable answers to users from day one.” said Ram Srivastav, CEO and co-founder of Cognika.
Amit Phansalkar, VP Products added, “The critical challenge in designing and conducting a clinical trial is to rely on services or manually search vast number of documents to reach decisions surrounding time and cost estimates for the clinical trial. I am highly thrilled to present this highly effective alternative to anyone involved with designing or operationally planning the clinical trial. The results and insights provided by Trial XL are based on knowledge gleaned from millions of journal articles; hundred thousand clinical trials, US and international, information, thousands of grants, and multiple other web sources. Trial XL effectively connects the dots in the information gathered thus providing the user critical insights that can restrict the delays in clinical trial. Trial XL gives every user the access to all this information making it an unmatched tool in the industry.”
Trial XL™ is generally available now. For more information please contact info[.]cognika.com. To request evaluation access please register at trialxl.com/.
Cognika Corporation (cognika.com) was founded with a mission to bring leading edge analytics tools developed at MIT to market. This breakthrough technology combines the best of Artificial Intelligence (AI) techniques with unique algorithms that emulate human cognition, and serves as the foundation for the Smart Analytics engine on which Cognika ESP™ is based. Cognika Corporation has expanded its technology to fully accommodate structured and unstructured data sources, including images and video. The company's current work includes novel solutions for automated analysis, design and optimization solutions, business intelligence, knowledge management, and anticipatory search for leading organizations in information-intensive industries such as life sciences, healthcare, process industry, defense, homeland security, telecommunications, and the financial sector.